Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9790366 | 0.80 | MTNR1A (0.57) | MTNR1AMTNR1BDRD2DRD3 | |
| SCHEMBL11036691 | 0.80 | MTNR1A (0.71) | MTNR1AMTNR1BDRD2DRD3 | |
| SCHEMBL23261875 | 0.77 | MAP3K14 (0.39) | MTNR1AMTNR1BDRD2 | |
| SCHEMBL23261947 | 0.77 | DRD2 (0.38) | MTNR1AMTNR1BDRD2DRD3HTR2A | |
| SCHEMBL10340613 | 0.77 | MAOA (0.48) | MTNR1AMTNR1BDRD2DRD3 | |
| SCHEMBL11019525 | 0.77 | MTNR1A (0.54) | MTNR1AMTNR1BDRD2DRD3 | |
| SCHEMBL10340388 | 0.77 | MTNR1A (0.67) | MTNR1AMTNR1BDRD2DRD3 | |
| SCHEMBL10340259 | 0.77 | MTNR1A (0.57) | MTNR1AMTNR1BADRA1AHTR2AHTR2C | |
| SCHEMBL9790351 | 0.77 | MTNR1A (0.46) | MTNR1AMTNR1BADRA1A | |
| SCHEMBL10340217 | 0.76 | MTNR1A (0.69) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0162695-B1 | 6-OXYGENATED-1,3,,4,5-TETRAHYDROBENZ(CD)INDOL-4-AMINES | SMITHKLINE BEECHAM CORPORATION (US) | 1990-01-17 | — | — | EP | claimed |
| EP-0162695-A1 | 6-Oxygenated-1,3,,4,5-Tetrahydrobenz(cd)indol-4-amines | SMITHKLINE BEECHAM CORPORATION (US) | 1985-11-27 | — | — | EP | claimed |
| EP-0360077-B1 | USE OF SEROTONIN ANTAGONISTS IN THE TREATMENT OF APOPLEXIA CEREBRI | Troponwerke GmbH & Co. KG (DE) | 1993-07-21 | — | — | EP | disclosed |
| EP-0332968-B1 | 1,3,4,5-Tetrahydrobenz[c,d]indoles | BAYER AG (DE) | 1993-06-02 | — | — | EP | disclosed |
| US-5021438-A | Having affinity for 5-hydroxytryptamine receptors; treating central nervous system and cardiovascular disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1991-06-04 | — | — | US | disclosed |
| EP-0360077-A2 | Use of serotonin antagonists in the treatment of apoplexia cerebri | Troponwerke GmbH & Co. KG (DE) | 1990-03-28 | — | — | EP | disclosed |
| EP-0162695-B1 | 6-OXYGENATED-1,3,,4,5-TETRAHYDROBENZ(CD)INDOL-4-AMINES | SMITHKLINE BEECHAM CORPORATION (US) | 1990-01-17 | — | — | EP | disclosed |
| EP-0332968-A1 | 1,3,4,5-Tetrahydrobenz[c,d]indoles | BAYER AG (DE) | 1989-09-20 | — | — | EP | disclosed |
| EP-0162695-A1 | 6-Oxygenated-1,3,,4,5-Tetrahydrobenz(cd)indol-4-amines | SMITHKLINE BEECHAM CORPORATION (US) | 1985-11-27 | — | — | EP | disclosed |